Clinical Trial Update: A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer [NA]

View source ↗

Summary

The clinical trial investigating LDE225 (sonidegib) as a biomarker-driven treatment for resectable pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• LDE225 (sonidegib)

Snippet

Sponsor: University of Utah | Conditions: Pancreatic Ductal Adenocarcinoma | NA | Status: WITHDRAWN